Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Immunodiagnostic Systems Holdings Plc LSE:IDH London Ordinary Share GB00B01YZ052 ORD 2P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 255.00 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
250.00 260.00 0.00 0.00 0.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 39.55 3.25 11.60 22.0 73
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 255.00 GBX

Immunodiagnostic Systems (IDH) Latest News

More Immunodiagnostic Systems News
Immunodiagnostic Systems Takeover Rumours

Immunodiagnostic Systems (IDH) Discussions and Chat

Immunodiagnostic Systems Forums and Chat

Date Time Title Posts
23/7/202015:40IDH with charts226
26/7/201806:16Immunodiagnostic Systems (IDH) One to Watch on Thursday -
20/6/201220:13IMMUNODIAGNOSTIC SYSTEMS HOLDINGS737
16/1/200908:38IDS - diagnostic testing kits for the clinical and research markets1

Add a New Thread

Immunodiagnostic Systems (IDH) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Immunodiagnostic Systems trades in real-time

Immunodiagnostic Systems (IDH) Top Chat Posts

DateSubject
09/8/2020
09:20
Immunodiagnostic Systems Daily Update: Immunodiagnostic Systems Holdings Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker IDH. The last closing price for Immunodiagnostic Systems was 255p.
Immunodiagnostic Systems Holdings Plc has a 4 week average price of 230p and a 12 week average price of 210p.
The 1 year high share price is 405p while the 1 year low share price is currently 167.50p.
There are currently 28,784,097 shares in issue and the average daily traded volume is 7,843 shares. The market capitalisation of Immunodiagnostic Systems Holdings Plc is £73,399,447.35.
23/7/2020
15:40
hedgehog 100: 23/07/2020 07:00 UKREG Immunodiagnostic Systems Hldgs PLC AGM Statement " ... COVID-19 Testing Range As announced on 30 June, we released our automated SARS-Cov2-IgG test in countries that accept the CE mark. Interest from our direct and distribution customers has been strong and initial feedback from their validation processes positive. The first sales of this test were made during July. We are hoping to launch a complimentary SARS-Cov2-IgM automated test in the coming months. Furthermore, we are also providing contract manufacturing services to a developer of an ELISA based test, and produced the first prototype batches in June and July. These products have great potential, though it is too early to estimate the revenue levels which they will generate. We are confident IDS have enough capacity for analyser instruments and assay manufacturing to meet likely demand. ..." https://uk.advfn.com/stock-market/london/immunodiagnostic-systems-IDH/share-news/Immunodiagnostic-Systems-Hldgs-PLC-AGM-Statement/82908683
01/7/2020
14:22
hedgehog 100: Well done and thanks to IDH's management for launching this COVID-19 antibody test bang on schedule, and for keeping the market so well updated. They look to have played an absolute blinder here in launching this 'platinum standard test' that could be a 'licence to print money'. And at just 270p IDH still isn't at much of a premium to the 240p+ that it was at for most of the spring, despite this game-changing development from the company. Though I would expect that to change over time. 30/06/2020 07:00 UKREG Immunodiagnostic Systems Hldgs PLC Launch of assay to detect SARS-CoV-2 antibodies "Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, announces that following the announcement on 12 June, our fully automated SARS-CoV-2 IgG antibody test ("the Test") will be available for sale from today. The test can now be purchased by customers in the UK, the EU, and a number of other countries which accept the CE mark as the basis of regulatory approval. We have commenced the process of working with various national reference centers and governmental bodies to ensure a roll-out according to national guidelines. Jaap Stuut, CEO of IDS commented "We are pleased to announce the release to the market of our automated SARS -CoV-2 antibody test, running on the IDS-iSYS analyser. IDS will now seek to commercialise this test via our direct sales force in Europe, and through our extensive distribution network elsewhere, and we look forward to joining the efforts to minimise the impact of the COVID-19 virus." About the Test The Test, which arises from the partnership between IDS and Technogenetics, is designed to run on the installed base of over 600 automated IDS-iSYS analysers. The Test: -- Detects specific IgG antibodies indicating past exposure to the COVID-19 virus and immune response; -- Is a quantitative test which determines antibody concentration (titer); -- Is highly accurate with a sensitivity of 100% and a specificity of 99.4%; -- Provides Test results available within 25 minutes. Unlike many COVID-19 serology assays currently available, this Test is a quantitative assay, thus it can determine the antibody concentration in patient serum. Although the clinical level of functional immunity conferred by SARS-CoV-2 IgG antibodies has not yet been determined, we believe quantitative tests may ultimately be valuable in determining immunity status based on the levels of antibody in the blood. All steps of the Test are automated with no manual reagent preparation required, ensuring minimal hands-on time for lab staff and a high daily throughput." http://uk.advfn.com/stock-market/london/immunodiagnostic-systems-IDH/share-news/Immunodiagnostic-Systems-Hldgs-PLC-Launch-of-assay/82752242
20/6/2020
20:30
hedgehog 100: Thanks for that 2toptrader. The negative impact of the lockdown on laboratory testing is very temporary, and we're already emerging from it. It will soon be forgotten. Whereas the massive need for COVID-19 testing will be ongoing, and this is what investors here will now focus on. And in this respect, IDH are planning to launch a range of COVID-19 antibody tests by the end of this month (i.e. the first quarter of their financial year), which could hardly be much more near-term : 17/06/2020 07:00 UKREG Immunodiagnostic Systems Hldgs PLC Final Results " ... Jaap Stuut, CEO of IDS, commented: "During FY2020 we delivered a second consecutive year of like for like revenue growth, with revenue increasing by 2% to GBP39.3m. We also increased the number of analysers sold or placed to 150, compared to 127 in FY2020. Adjusted EBITDA improved to GBP6.1m from GBP4.8m in the prior year. Our results in Q1 of FY2021 will be significantly impacted by reduced laboratory testing volumes, however once the pandemic subsides, we believe we are in a strong position to continue our revenue growth. Additionally, we have an opportunity to commercialise our range of automated and manual SARS-CoV-2 antibody testing kits, which we plan to launch during June 2020. ... In the short term we will also focus on commercialising opportunities arising from Increased levels of SARS-CoV2 antibody testing using a range of automated and manual test kits which we expect to launch during Q1 FY2021. ..." https://uk.advfn.com/stock-market/london/immunodiagnostic-systems-IDH/share-news/Immunodiagnostic-Systems-Hldgs-PLC-Final-Results/82674591
17/6/2020
17:04
hedgehog 100: IDH is a former 20-bagger. And it has plenty of facilities and cash to help address the COVID-19 testing shortage. This could fuel another great period of share price performance. IDH's current market cap. is £80.6M. at 280p, of which over a third is covered by its cash of about £28M. And this is a nice market cap. for a growing business to achieve a stellar rating from. Because tracker funds are forced to buy in as the share price and market cap. rise. This dynamic helped to fuel IDH's stellar rise to over £12 a share about a decade ago.
17/6/2020
15:25
hedgehog 100: It was a 'fake drop' early this morning: virtually all buys today, and at 280p the share price is now up on the day. IDH has a lot going on regarding the massive COVID-19 opportunity, and the company promises to update the market re. any significant developments: 17/06/2020 07:00 UKREG Immunodiagnostic Systems Hldgs PLC Final Results " ... 7. Outlook ... We are working to manufacture and commercialise CLIA and ELISA tests to detect SARS-CoV-2 antibodies, combining our resources and capabilities with partners who complement our skill set with their virology know-how. A summary of the opportunities we are working on is set out in Jaap's CEO report, and we will update the market via RNS if there is any significant news in this area. ... Opportunities We are currently in negotiations with a number of partners to manufacture and commercialise COVID-19 antibody test kits in both ELISA and CLIA formats. We are currently working to manufacture and commercialise COVID-19 antibody test kits in both ELISA and CLIA formats, combining our resources and capabilities with partners who have knowledge in virology and infectious diseases. Our development partner, Technogenetics, has developed a COVID-19 IgG assay to detect SARS-CoV-2 antibodies. This quantitative automated assay which runs on the IDS-iSYS analyser, should be available for sale by IDS before the end of June, in Europe and distribution regions whose regulatory regime is based on the CE-mark. In addition, we have agreed commercial terms with a UK based specialist medical diagnostics company to produce components of their COVID-19 ELISA manual assay. Finally, we are working with a number of partners with expertise in virology and immunology to provide a route to market for ELISA-based COVID-19 assays, utilising our direct sales organisation as well as our extensive distribution network. ..." https://uk.advfn.com/stock-market/london/immunodiagnostic-systems-IDH/share-news/Immunodiagnostic-Systems-Hldgs-PLC-Final-Results/82674591 I think that we can expect some very exciting IDH newsflow over the summer, which should help drive the share price to much higher levels.
12/6/2020
09:00
farukequity: whoever is running PR & Investor Relations department in this business should be fired on the spot. keeping things under wraps is not how you create shareholder value in the 21st century. imagine if they issued an announcement initially they are working on a quantitative antibody test & leveraging all the unique advantages of their underlying business - the share price would be 2-3x higher before today's announcement already. hope they are doing Zoom calls with media & institutions 24 f...ing 7 right now to make people aware of what they have. for all of the small retail investors like yours truly, at least they are at the top of today's leader boards, so thousands of people will be looking at this company and scratching their heads just like me. these guys have the final product, distribution network and unit economics all ready - and the explosive share price rise is just beginning
25/4/2020
16:47
hedgehog 100: Guys, Immunodiagnostic's current COVID-19 offering is a 'picks & shovels' play. And remember where that phrase comes from During the California Gold rush in the 19th century the most reliable way to get rich was reportedly to sell picks and shovels etc to the gold prospectors, rather than actually staking a claim. "Manufacturing Support for COVID-19 Manufacturing Support As the world struggles to contain the novel coronavirus (COVID-19) outbreak, it becomes clear that diagnostics test availability is a key constraint. To support our healthcare systems with this challenge, we need to rapidly move production resources into this area. We at Immunodiagnostic Systems (IDS) want to play a part in the global effort fighting this pandemic. Therefore, we would like to offer our expertise and support in manufacturing ELISA kits for those companies with a COVID-19 diagnostic test that need more production capacity. What we can provide IDS is a leading in vitro diagnostic solution provider to the clinical laboratory market. We develop, manufacture and market innovative immunoassays and automated immunoanalyser technologies to provide improved diagnostic outcomes for patients. We can offer large scale ELISA plate production, from initial formulation to packaging, labelling and shipment in our ISO 13485 and cGMP qualified facilities in Italy and the United Kingdom. If you would like to learn more about how we can support your manufacturing efforts or require further information, please contact us on info@idsplc.com. Let’s work together and make the world a safer place." HTTP://www.idsplc.com/uncategorised/covid19support/ "ELISA ... The enzyme-linked immunosorbent assay (ELISA) ... has been used as a diagnostic tool in medicine, plant pathology, and biotechnology, as well as a quality control check in various industries. In the most simple form of an ELISA, antigens from the sample are attached to a surface. Then, a matching antibody is applied over the surface so it can bind to the antigen. This antibody is linked to an enzyme, and in the final step, a substance containing the enzyme's substrate is added. The subsequent reaction produces a detectable signal, most commonly a color change. ..." https://en.wikipedia.org/wiki/ELISA Mass diagnostic testing SHOULD be a game changer in the fight against coronavirus, but there's a global shortage of production capability for this. IDH is helping to address this, so this SHOULD be a game changer for the company. Indeed it's a major, lasting business opportunity for IDH, which is clearly moving fast to address this opportunity. For multiple existing partners, and multiple new partners: 17/04/2020 16:35 UKREG Immunodiagnostic Systems Hldgs PLC FY20 Trading Update " ... We are offering our production facilities, and sales network, to several new and existing partners who are in the process of developing COVID-19 test kits. ..." https://uk.advfn.com/stock-market/london/immunodiagnostic-systems-IDH/share-news/Immunodiagnostic-Systems-Hldgs-PLC-FY20-Trading-Up/82254353
22/4/2020
16:59
hedgehog 100: IDH is a very substantial company, which is looking massively undervalued given the current shortage of COVID-19 testing capacity. Here are the IDH figures: Full year revenue for year ending 30.3.20: £39.3M. (an increase on 2019). Cash at 31.3.20: £27.6M. (an increase on the year). https://uk.advfn.com/stock-market/london/immunodiagnostic-systems-IDH/share-news/Immunodiagnostic-Systems-Hldgs-PLC-FY20-Trading-Up/82254353 Current market cap. at 225p: £64.76M. Less cash, = £37.16M. for the business above cash levels. I.e. a revenue multiple of under one times revenue. Omega Diagnostics (ODX) in comparison: Half year revenue of £4.46M., a fall from previous first half. As at 30.9.19: No net cash. Net current liabilities £3M. Half year loss of £0.29M. https://uk.advfn.com/stock-market/london/omega-diagnostics-ODX/share-news/Omega-Diagnostics-Group-PLC-Interim-Results/81256223 Current market cap. at 32p: £48.58M. I.e. a revenue multiple of over five times annualised revenue.
22/4/2020
15:44
hedgehog 100: IDH is a former 20-bagger. And it has plenty of facilities and cash to help address the COVID-19 testing shortage. This could fuel another great period of share price performance.
22/4/2020
15:16
hedgehog 100: Speaking of Omega Diagnostics, its share price has been doing rather well recently, multibagging from 7.625p at the start of this month to its current share price of 31p. Fueled by announcements that it is to manufacture COVID-19 tests. And IDH looks like it will also be entering into such agreements shortly, judging from its recent trading update. But the market doesn't seem to have picked up on this yet. Probably because IDH is currently 'under the radar screen' of most investors, and the RNS was released after close on Friday (17th. April). 17/04/2020 16:35 UKREG Immunodiagnostic Systems Hldgs PLC FY20 Trading Update " ... Cash position Closing cash and cash equivalents were GBP27.6m at 31 March 2020 (31 March 2019: GBP27.7m). ... Looking forward So far in April 2020 we have seen a reduction in revenue versus the same period last year, caused by a reduction in routine medical testing in hospitals and laboratories as their focus has been on COVID-19 treatment and testing. IDS intend to take appropriate action, including utilising the various schemes available from governments to provide business support, to minimise our costs during this period of uncertainty. From a liquidity perspective, IDS is in a very strong position with cash holdings of almost GBP28m. We are offering our production facilities, and sales network, to several new and existing partners who are in the process of developing COVID-19 test kits. ... " https://uk.advfn.com/stock-market/london/immunodiagnostic-systems-IDH/share-news/Immunodiagnostic-Systems-Hldgs-PLC-FY20-Trading-Up/82254353
Immunodiagnostic Systems share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
IDH
Immunodiag..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200810 06:12:13